| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| ln Vitro |
Zinc phthalocyanine (ZnPc) and its derivatives (pyridinoyzinc phthalocyanine ((py)ZnPc), zinc octaphenoxypthhalocyanine (ZnOPPc), and zinc octaestronepthhalocyanine (ZnOEPc)) were studied for their photophysical and photochemical properties in various solvents. Their ability to generate singlet oxygen (ΦΔ) and undergo photobleaching (Φp) was quantified, and their fluorescence quantum yields (ΦF) were measured. These properties are relevant to their potential as photosensitizers in applications like Photodynamic Therapy (PDT). For example, ZnPc showed singlet oxygen quantum yields (ΦΔ) ranging from 0.56 in DMF to 0.67 in DMSO. [1]
The ground state electronic absorption spectra (Q-band) of ZnPc exhibited solvent-dependent red shifts, with the largest shift observed in aromatic solvents like 1-chloronaphthalene. This shift was primarily attributed to solvation/polarization effects rather than coordination. [1] Some derivatives showed aggregation or distortion effects in specific solvents, which influenced their spectral properties and photochemical behavior. For instance, ZnOPPc in THF showed an extra absorption band at 698 nm and underwent phototransformation instead of photobleaching upon irradiation. [1] |
|---|---|
| References |
|
| Additional Infomation |
Metal phthalocyanine compounds, such as zinc phthalocyanine (ZnPc), have attracted much attention for their photosensitization in photodynamic therapy (PDT). In PDT, after the photosensitizer is excited, it transfers energy to ground-state oxygen via a type II mechanism, thereby generating cytotoxic singlet oxygen. [1] This study focuses on the effects of different solvents on the photochemical properties (singlet oxygen generation, photobleaching) and fluorescence properties of ZnPc and its three derivatives (py) ZnPc, ZnOPPc and ZnOEPc. Solubility can be improved by peripheral or axial substitution, and its properties may be tailored for specific applications (e.g., ZnOEPc with estrone substituents is considered a potential third-generation photosensitizer with selectivity). [1] Key findings include: Aromatic solvents cause the largest redshift in Q-band absorption. THF exhibits unique properties, generally producing higher fluorescence quantum yields, and for ZnOPPc, it causes photoconversion rather than photobleaching. The observed properties are significantly influenced by solvent parameters such as refractive index, donor number, and solvent-induced aggregation or molecular distortion. [1]
|
| Molecular Formula |
C32H16N8-2.ZN+2
|
|---|---|
| Molecular Weight |
577.91304
|
| Exact Mass |
576.078
|
| CAS # |
14320-04-8
|
| PubChem CID |
2735172
|
| Appearance |
Purplish red to black solid powder
|
| LogP |
1.148
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
41
|
| Complexity |
1080
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PODBBOVVOGJETB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H16N8.Zn/c1-2-10-18-17(9-1)25-33-26(18)38-28-21-13-5-6-14-22(21)30(35-28)40-32-24-16-8-7-15-23(24)31(36-32)39-29-20-12-4-3-11-19(20)27(34-29)37-25;/h1-16H;/q-2;+2
|
| Chemical Name |
zinc;2,11,20,29,37,39-hexaza-38,40-diazanidanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1,3,5,7,9,11,13,15,17,19(39),20,22,24,26,28,30(37),31,33,35-nonadecaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : 2.7 mg/mL (~4.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7304 mL | 8.6519 mL | 17.3037 mL | |
| 5 mM | 0.3461 mL | 1.7304 mL | 3.4607 mL | |
| 10 mM | 0.1730 mL | 0.8652 mL | 1.7304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
